Chemoprevention of patients with hepatitis B receiving chemotherapy or bone marrow transplant

Current Hepatitis Reports

Volumn 9, Issue 3, 2010, Pages 178-186

  Gopal, Kavitha ^a   Min, Albert D ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Bone marrow transplantation; Chemoprevention; Hepatitis B virus; Hepatitis B virus reactivation; Immunosuppression

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISONE; TELBIVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ANTIBODY; VINCRISTINE;

AWARENESS; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HEPATITIS B; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; NONHODGKIN LYMPHOMA; RECURRENT VIRUS INFECTION; REVIEW; RISK FACTOR; SCREENING TEST; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 77955983404     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-010-0048-0     Document Type: Review

References (72)

1. Lok AS, Lai CL, Wu PC, et al.: Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 1987, 126:492-499.
2. Yeo W, Chan PK, Zhong S, et al.: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 63:299-307.
3. Hoofnagle JH, Dusheiko GM, Schafer DF, et al.: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982, 96:447-449.
4. Nakamura Y, Motokura T, Fujita A, et al.: Severe hepatitis related to chemotherapy in hepatitis carriers with hematologic malignancies: survey in Japan, 1987-1991. Cancer 1996, 78:2210-2215.
5. Vassiliadis T, Garipidou V, TziomalosK, et al: Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologicmalignancies treated with chemotherapy - a prospective case series. Am J Hematol 2005, 80:197-203.
6. Lok AS: Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 1992, 10:46-52.
7. Mindikoglu AL, Regev A, Schiff ER: Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006, 4(9):1076-1081.
8. Lau GK, Yiu HH, Fong DY, et al.: Early is superior to deferred preemptive therapy for hepatitis undergoing chemotherapy. Gastoenterology 2003, 125:1742-1749.
9. Perrillo RP: Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009-1022.
10. Thung SN, Gerber MA, Klion F, Gilbert H: Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 1985, 145:1313-1314.
11. Lau GK, He ML, Fong DY, et al.: Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002, 36(3):702-709.
12. Idilman R, Arat M, Soydan E, et al: Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004, 11:141-147.
13. Cheng AL: Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non- Hodgkin's lymphoma. Blood 1996, 87:1202.
14. Ohtsu T, Sai T, Oka M, et al.: Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 1991, 21:360-365.
15. Hoofnagle JH: Reactivation of hepatitis B. Hepatology 2009, 49(5 Suppl):S156-S65.
16. Yeo W, Hui EP, Chan AT, et al.: Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005, 28:379-384.
17. Yeo W, Johnson PJ: Diagnosis, prevention, and management of hepatitis B virus during anticancer therapy. Hepatology 2006, 43:209-220.
18. Yeo W, Chan TC, Leung NW, et al.: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27:605-611.
19. Iannitto E, Minardi V, Calvaruso G, et al.: Hepatitis B virus reactivation and alemtuzumab therapy [published erratum appears in Eur J Haematol 2005, 75:183]. Eur J Haematol 2005, 74:254-258.
20. Lok AS, Liang RH, Chiu EK, et al.: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991, 100:182-188.
21. Yeo W, Zee B, Zhong S, et al.: Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Brit J Cancer 2004, 90:1306-1311.
22. Zhong S, Yeo W, Schroder C, et al.: High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepatol 2004, 11:55-59.
23. Hui CK, Bowden S, Jackson K, et al.: Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood 2005, 10:2616-2617.
24. Hammond SP, Borchelt AM, Ukomadu C, et al.: Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:1049-1059.
25. Kawatani T, Suou T, Tajima F, et al.: Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001, 67:45-50.
26. Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662. Updated practice guidelines from the American Association for the Study of Liver Diseases for management of hepatitis B.
27. European Association for the Study of the Liver: Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242. Practice guidelines from the European Association for the Study of Liver Diseases regarding management of hepatitis B.
28. Keeffe EB, Dieterich DT, Han HB, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6:1315-1341.
29. Lubel JS, Testro AG, Angus PW: Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007, 37:705-712.
30. Locarnini S: Molecular virology of hepatitis B virus. Semin Liver Dis 2004, 24(Suppl 1):3-10.
31. Hsu C, Hsiung CA, Su IJ, et al.: A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008, 47:844-853. A recent randomized controlled trial evaluating administration of prophylactic lamivudine versus therapeutic lamivudine in chemotherapy-associated hepatitis B reactivation among patients with non-Hodgkin's lymphoma. Prophylactic lamivudine use reduced the incidence and severity of chemotherapy-related HBV compared to therapeutic lamivudine use.
32. Leaw SJ, Yen CJ, Huang WT, et al.: Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004, 83:270-275.
33. Li YH, He YF, Jiang WQ, et al.: Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006, 106:1320-1325.
34. Jang JW, Choi JY, Bae SH, et al.: A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006, 43(2):233-240.
35. Katz LH, Fraser A, Gafter-Gvili A, et al.: Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008, 15:89-102.
36. Ziakas PD, Karsaliakos P, Mylonakis E: Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009, 94:998-1005.
37. Loomba R, Rowley A, Wesley R, et al.: Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy [published erratum appears in Ann Intern Med 2009, 150:657-658]. Ann Intern Med 2008, 148:519-528. This metaanalysis showed that preventive therapy with lamivudine for patients who test positive for HBsAg and are undergoing chemotherapy may reduce the risk for HBV reactivation and HBVassociated morbidity and mortality.
38. Hui CK, Cheung WW, Au WY, et al.: Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005, 54:1597-1603.
39. Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007, 11:965-991.
40. Dhédin N, Douvin C, Kuentz M, et al.: Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998, 66:616-619.
41. Seth P, Alrajhi AA, Kagevi I, et al.: Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 2002, 30:189-194.
42. Onozawa M, Hashino S, Izumiyama K, et al.: Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005, 79:616-619.
43. Foont JA, Schiff ER: Avoid the tragedy of hepatitis B reactivation in immunosuppressed patients. Nat Clin Pract Gastroenterol Hepatol 2007, 4:128-129.
44. Lok AS, Liang RH, Chiu EK, et al.: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991, 100:182-188.
45. Torbenson M, Thomas DL: Occult hepatitis B. Lancet Infect Dis 2002, 2:479-486.
46. Awerkiew S, Däumer M, Reiser M, et al.: Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007, 38:83-86.
47. Ferraro D, Pizzillo P, Di Marco V, et al.: Evaluating the risk of hepatitis B reactivation in patients with haematologicalmalignancies: is the serum hepatitis B virus profile reliable R. Liver Int 2009, 29:1171-1177.
48. Strasser SI, McDonald GB: Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood 1999, 93:1127-1136.
49. Piekarska A, Zaucha JM, Hellmann A, McDonald GB: Prevention of hepatitis B virus transmission from an infected stem cell donor. Bone Marrow Transplant 2007, 40:399-400.
50. Knöll A, Boehm S, Hahn J, et al.: Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 2007, 14:478-483.
51. Ma SY, Au WY, Ng IO, et al.: Hepatic graft versus host disease after hematopoietic stem cell transplantation: clinicopathologic features and prognostic implication. Transplantation 2004, 77:1252-1259.
52. Lau GK, Liang R, Chiu EK, et al.: Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant 1997;19:795-799.
53. Lau GK, Liang R, Lee CK, et al.: Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core and anti-hepatitis B surface antibody positive. J Infect Dis 1988, 178:1585-1591.
54. Lau GK, Suri D, Liang R, et al.: Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002, 122:614-624.
55. Lau GK, Yuen ST, Au WY, et al.: Histological changes during clearance of chronic hepatitis B virus infection by adoptive immune transfer. J Gastroenterol Hepatol 1999, 14:262-268.
56. Guidotti LG, Chisari FV: Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001, 19:65-91.
57. Herbein G, O'Brien WA: Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000, 223:241-257.
58. Oniankitan O, Duvoux C, Challine D, et al.: Infliximab therapy for rheumatic disease in patients with chronic hepatitis B or C. J Rheumatol 2004, 31:107-109.
59. Ostuni P, Botsios C, Punzi L, et al.: Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis reated with infliximab and low dose of methotrexate. Ann Rheum Dis 2003, 62:686-687.
60. Wendling D, Auge B, Bettinger D, et al.: Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis. 2005; 64:788-789.
61. Ueno Y, Tanaka S, Shimamoto M, et al.: Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005, 50:163-166.
62. Michel M, Duvoux C, Hezode C, Cherqui D: Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for adult onset Still's disease. J Rheumatol 2003, 30:1624-1625.
63. Esteve M, Saro C, González-Huix F, et al.: Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53:1363-1365.
64. Calabrese LH, Zein N, Vassilopoulos D: Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004, 63(Suppl 2):ii18-ii24.
65. del Valle García-Sanchez M, Gómez-Camacho F, Poyato- González A, et al.: Infliximab therapy in a patient with Crohn's disease and chronic hepatitis virus infection. Inflamm Bowel Dis 2004, 10:701-702.
66. Ojiro K, Naganuma M, Ebinuma H, et al.: Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008, 43:397-401.
67. Papa A, Mocci G, Bonizzi M, et al.: Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol 2009, 104(6):1575-1586.
68. Hui CK, Cheung WW, Zhang HY, et al.: Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy [published erratum appears in Gastroenterology 2006, 131:1363]. Gastroenterology 2006, 131:59-68.
69. Weinbaum CM, Williams I, Mast EE, et al.; Centers for Disease Control and Prevention: Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008, 57(RR-8):1-20.
70. Tran TT, Rakoski MO, Martin P, Poordad F: Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Ther 2010, 31:240-246. This study investigated the current practice among oncologists regarding HBV screening and antiviral prophylaxis prior to starting chemotherapy. Data showed 20% of oncologists never screen for HBV prior to initiating chemotherapy. Greater education regarding risk of HBV reactivation is needed for clinicians treating patients with immunosuppressive therapies.
71. Les I, García-Martínez R, Córdoba J, et al.: Current trends in chronic hepatitis B management: results of a questionnaire. Eur J Gastroenterol Hepatol 2009, 21:1177-1183.
72. Khokhar OS, Farhadi A, McGrail L, Lewis JH: Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy 2009, 55:69-75.